Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
Whatslove AI: Best AI Girlfriend for Scenario Video Roleplay 2026
Cathryn Robinson’s Seven Steps to Ditch Anxiety Offers a Practical and Empowering Blueprint for Emotional Resilience
Memoir Coarse Evolution by Wesley Adcock Chronicles a Journey from Childhood Adversity to Faith-Fueled Change
Eternity Bowling to Showcase String Bowling EV99 at Major 2026 Industry Exhibitions
Authors Draw on Careers in Public Service and Aviation to Chronicle Life Abroad
Alienware AW3926QW Review: 39 Inches of Gaming Glory
Bank of England set for new innovation mandate covering stablecoins
The Rock Zanzibar: The Story Behind One of the Indian Ocean’s Most Extraordinary Restaurants
Honey, I shrunk the wine: why miniature bottles are big again
Festivalgoers brave heavy rain on wet first day
EXOPAY Builds A Blockchain Finance Network Connecting Digital Assets With Everyday Commerce
Dame Jenni Murray died days after car crash, inquest hears
New Releаse Lаugh, Cry, Criticize Delivers 100+ Flаsh Fiction Stories Thаt Pаck аn Emotionаl Punch
Jes Staley told Congress it was ‘incredible’ Epstein’s abuse continued after jail
Is AI making workers more vulnerable?
Best Posture Correctors for Better Body Alignment (2026)
High in cocoa, high on nostalgia: the chocolate I love most now
Bitcoin faces true demand test above $83K as liquidity thickens: Glassnode
Visit Malaysia… in London: A Taste of Malaysia Comes to Battersea This September
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.